MagPortal.com   "Clients return to our site because of the research capabilities provided by MagPortal.com — research that is not commonly found on most websites."
  – John Houston, SVP, Raymond James Financial Services
 Home  |  News Feeds  |  Stock Market  |  Newsletter  |  My Articles  |  My Account  |  Affiliate Program  |  Help 

Location: Categories / Business / Industries / Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.
See Also
Health
Health / Illness, Injury & Treatments
Health / Medical Practice
Science & Technology / Biology & Life Sciences
Current Medical Articles
TIME Europe
February 15, 2010
Kathleen Kingsbury
Prescription for a Turnaround New CEO George Barrett gets Cardinal Health refocused on the supply chain. mark for My Articles similar articles
BusinessWeek
February 4, 2010
Dermot Doherty
The New Man at Novartis CEO Joe Jimenez says his consumer-products background, with stints at Clorox and Heinz, will be a booster for the drugmaker. mark for My Articles similar articles
Chemistry World
February 4, 2010
Matt Wilkinson
More pharma R&D budget cuts GlaxoSmithKline (GSK) and Pfizer are both following AstraZeneca's lead in cutting their research and development budgets. mark for My Articles similar articles
The Motley Fool
February 4, 2010
Brian Orelli
A Drugless Drugmaker IPO! Biotech investors embrace risk ... sort of. The most exciting thing about Ironwood's IPO? The company doesn't have any drugs on the market. mark for My Articles similar articles
The Motley Fool
February 4, 2010
Brian Orelli
Glaxo Brings Home the Bacon Swine flu gives GlaxoSmithKline the boost, but how long will it last? mark for My Articles similar articles
The Motley Fool
February 4, 2010
Brian Orelli
Surfing the Wave of the Future: Personalized Medicine Medco buys in to personalized medicine. Yesterday Medco Health Solutions said it's purchasing genetic-testing expert DNA Direct. mark for My Articles similar articles
The Motley Fool
February 3, 2010
Brian Orelli
Wyeth Can't Save Pfizer Not much earnings growth, but the price is right. mark for My Articles similar articles
The Motley Fool
February 3, 2010
Brian Orelli
Pfizer's Hedge Pays Off FDA wants more data from Pfizer's partner, Protalix on their treatment for Gaucher disease. mark for My Articles similar articles
InternetNews
February 2, 2010
UCSF Patients Latest Data Breach Victims A laptop containing the personal information of more than 4,300 patients receiving care at the University of California, San Francisco medical school was stolen in November. mark for My Articles similar articles
The Motley Fool
February 2, 2010
Brian Orelli
Shaking Up the Biotech Industry A judge will decide if genes are patentable or not. mark for My Articles similar articles
The Motley Fool
February 2, 2010
Brian Orelli
Foolish Forecast: First Look at Pfizer Plus With the addition of Wyeth last quarter, there's no doubt Pfizer is larger, but whether that bigger size translates into savings that boosts profits remains to be seen. mark for My Articles similar articles
TIME Europe
February 8, 2010
Bonnie Rochman
Group Therapy Why so many patients are sharing their medical data online. mark for My Articles similar articles
InternetNews
February 1, 2010
Apple's iPad a Boon to Health Care Providers? Steve Jobs didn't mention it at the product's debut, but the iPad's specs and design position it as a good point-of-care device for health care professionals and telemedicine applications. mark for My Articles similar articles
The Motley Fool
February 1, 2010
Brian Orelli
Now That's Some Expensive Risk Mitigation Boston Scientific avoids a trial -- but at a dear cost. mark for My Articles similar articles
CRM
February 2010
Lauren McKay
The New-Age Home Aided by SiteSpect, a specialist in elder-care placement boosts Web conversions and better addresses client needs. mark for My Articles similar articles
The Motley Fool
January 29, 2010
Brian Orelli
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. mark for My Articles similar articles
The Motley Fool
January 29, 2010
Brian Orelli
Wake Up! You Still Have to Pay Attention We already knew Celgene's preliminary numbers, but the conference call offers a look ahead. mark for My Articles similar articles
The Motley Fool
January 29, 2010
Brian Orelli
Icahn Back to Batter Biogen The old guy has tenacity. mark for My Articles similar articles
The Motley Fool
January 29, 2010
Brian Orelli
All Grown Up, With Cash to Burn Bristol-Myers is all drugs, all the time. mark for My Articles similar articles
Chemistry World
January 28, 2010
Nina Notman
AstraZeneca's workforce slashed again Pharma giant AstraZeneca is to cut another 8,000 jobs globally over the next four years - with approximately 1,800 additional research and development staff to be lost. mark for My Articles similar articles
The Motley Fool
January 28, 2010
Brian Orelli
Health-Care Reform Is Dead. Probably. Breaking up the bill doesn't seem like the answer. What do insurers and pharmaceutical companies have to say? mark for My Articles similar articles
The Motley Fool
January 28, 2010
Brian Orelli
The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren. mark for My Articles similar articles
The Motley Fool
January 28, 2010
Brian Orelli
Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds. mark for My Articles similar articles
The Motley Fool
January 28, 2010
Brian Orelli
The Next Amgen? Not Yet. Amylin Pharmaceuticals is in much the same situation as Amgen is in: relatively flat sales, and the potential for a nice boost from a Food and Drug Administration approval shortly. But that's where the comparison ends. mark for My Articles similar articles
The Motley Fool
January 28, 2010
Brian Orelli
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. mark for My Articles similar articles
The Motley Fool
January 27, 2010
Brian Orelli
Humira or Not, Abbott's on a Roll Investors worry about how Abbott's Humira is such a large fraction of the company's revenue, and then when the company turns in a nice quarter even without strong U.S. sales of Humira, they complain about that. mark for My Articles similar articles
The Motley Fool
January 27, 2010
Brian Orelli
Nice, Novartis, Very Nice CEO Daniel Vasella leaves on a high note. mark for My Articles similar articles
The Motley Fool
January 27, 2010
Brian Orelli
The Virus-Killer's Killer Quarter Gilead Sciences closed out 2009 with a solid 42% increase in revenue in the fourth quarter, thanks to its HIV drugs. mark for My Articles similar articles
The Motley Fool
January 26, 2010
Brian Orelli
Timing Is Everything for Amgen Amgen is counting on osteoporosis drug Prolia for a successful 2010. mark for My Articles similar articles
The Motley Fool
January 26, 2010
Brian Orelli
Is Victoza's Victory in Vain? Novo Nordisk finally gets the FDA to sign off on its once-daily diabetes drug. mark for My Articles similar articles
The Motley Fool
January 26, 2010
Dave Mock
A Big Upgrade for Cepheid Enough top-performing Motley Fool CAPS members have recently moved to the bull side of Cepheid to upgrade the molecular diagnostics firm from its four-star rank to a top-rated five stars. mark for My Articles similar articles
The Motley Fool
January 25, 2010
Brian Orelli
Pay-for-Delay Is Under the Spotlight It helps each side, but governments aren't thrilled with the idea. mark for My Articles similar articles
The Motley Fool
January 25, 2010
Brian Orelli
No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday. mark for My Articles similar articles
The Motley Fool
January 25, 2010
Brian Orelli
Tysabri Updates: All You Have to Do Is Ask Biogen Idec is willing to hook medical doctors up with an automatic monthly update of the number of progressive multifocal leukoencephalopathy cases for people taking it and Elan's multiple sclerosis drug, Tysabri. mark for My Articles similar articles
Nurse Practitioner
February 2010
Jennifer M. Belavic
Drug approvals '09 in review On May 13, 2009, the FDA approved certolizumab pegol, marketed under the brand name Cimzia, for the treatment of moderately to severely active RA. mark for My Articles similar articles
The Motley Fool
January 22, 2010
Brian Orelli
Pfizer's Great Data Won't Do Much The full data from a clinical trial testing Pfizer's Sutent in pancreatic cancer was truly amazing. Unfortunately, it's not going to do very much for the stock or Pfizer's bottom line. mark for My Articles similar articles
The Motley Fool
January 22, 2010
Brian Orelli
Intuitive Surgical Makes Me a Winner! Hysterectomies are poised to pass prostatectomies as the company's growth driver. mark for My Articles similar articles
Fast Company
February 2010
Paul Hochman
Bionic Legs, i-Limbs, and Other Super Human Prosheses You'll Envy Save your tears for Tiny Tim. A boom in sophisticated prostheses has created a most unlikely by-product: envy. mark for My Articles similar articles
Fast Company
February 2010
Nathaniel Whittemore
How Cell Phone-Powered Labs Could Transform Medical Diagnostics in Africa A social enterprise's invention could transform medical diagnostics in the developing world. mark for My Articles similar articles
Fast Company
February 2010
Kate Rockwood
An In-Depth Look at the Hospital of the Future The hospital of the future is designed not just to heal the sick but also to help sustain the environment. mark for My Articles similar articles
Philanthropy
January 1, 2010
Adam Keiper
Breakthrough Medical research is dominated by government and corporate funding. How can philanthropic dollars find a distinctive niche? mark for My Articles similar articles
Chemistry World
January 20, 2010
Phil Taylor
Screw tightens on pay-for-delay drug deals Scrutiny of the tactics used by pharmaceutical companies to delay the entry of generics onto the market is rising on both sides of the Atlantic amid claims that the practice is costing consumers billions every year. mark for My Articles similar articles
National Defense
February 2010
Austin Wright
Deployable Brain Scanner Could Help Treat Soldiers' Head Injuries John E. Kimura, the president and CEO of Sensorium Inc., believes his system will allow neurologists in the United States to peer into the heads of wounded soldiers in remote areas. mark for My Articles similar articles
Chemistry World
January 6, 2010
Ned Stafford
UK libel laws threaten scientific debate A libel lawsuit brought by GE Healthcare has succeeded in silencing an eminent Danish radiologist who questioned the safety of one of the firm's drugs, but the firm is now being accused by some in the scientific community of trying to stifle legitimate scientific discussion. mark for My Articles similar articles
There are 6318 old articles available for this category.